Radiation Toxicity clinical trials at UCSF
1 in progress, 0 open to eligible people
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
Sorry, in progress, not accepting new patients
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.
San Francisco, California
Our lead scientists for Radiation Toxicity research studies include Mack Roach, MD.